erlotinib hydrochloride has been researched along with alpha-aminopyridine in 8 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (alpha-aminopyridine) | Trials (alpha-aminopyridine) | Recent Studies (post-2010) (alpha-aminopyridine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 5,813 | 460 | 3,246 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | alpha-aminopyridine (IC50) |
|---|---|---|---|
| Botulinum neurotoxin type A | Clostridium botulinum | 1.8 | |
| Nitric oxide synthase, endothelial | Homo sapiens (human) | 2.8 | |
| Nitric oxide synthase, brain | Homo sapiens (human) | 6 | |
| Nitric oxide synthase, brain | Rattus norvegicus (Norway rat) | 9 | |
| Nitric oxide synthase, inducible | Homo sapiens (human) | 1.9 | |
| Phosphatidylinositol 4-kinase alpha | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase type 2-beta | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase type 2-alpha | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase beta | Homo sapiens (human) | 7.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishikawa, D; Kita, K; Matsumoto, K; Mitsudomi, T; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Sekido, Y; Suda, K; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Antonakos, B; Cooke, VG; Danial, NN; Flemming, D; Hurov, KE; Jones, MD; Korn, JM; Ledell, J; Lehár, J; Mishina, Y; Schoumacher, M; Sellers, WR; Shao, W; Sonkin, D; Steiger, J; Stump, MD; Yan-Neale, Y | 1 |
| Alagesan, B; Bardeesy, N; Benes, CH; Contino, G; Corcoran, RB; Deshpande, V; Engelman, J; Guimaraes, AR; Hezel, AF; Loda, M; Weissleder, R; Wojtkiewicz, GR; Wong, KK | 1 |
| Goldman, JW; Hurt, KC; Koustenis, A; Paz-Ares, L; Reck, M; Shi, P | 1 |
| Amin, AR; Anisuzzaman, AS; Chen, Z; Chen, ZG; Haque, A; Rahman, MA; Shin, DM; Wang, D; Zhang, C | 1 |
| Benes, CH; Damon, LJ; Dardaei, L; Dastur, A; Dicecca, R; Engelman, JA; Farago, AF; Fintelmann, FJ; Friboulet, L; Gainor, JF; Greenberg, M; Held, MA; Kattermann, KE; Kodack, DP; Lee, D; Niederst, MJ; Parks, M; Piotrowska, Z; Riley, AK; Rizzo, C; Sequist, LV; Shaw, AT; von Flotow, F | 1 |
| Higo, H; Hotta, K; Ichihara, E; Kano, H; Kayatani, H; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Matsubara, T; Ninomiya, K; Ninomiya, T; Nishii, K; Ohashi, K; Rai, K; Sato, A; Tabata, M; Takata, M; Tomida, S; Toyooka, S; Watanabe, H | 1 |
1 trial(s) available for erlotinib hydrochloride and alpha-aminopyridine
| Article | Year |
|---|---|
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutati
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Palliative Care; Prognosis; Proto-Oncogene Proteins p21(ras); Salvage Therapy; Survival Rate; Young Adult | 2016 |
7 other study(ies) available for erlotinib hydrochloride and alpha-aminopyridine
| Article | Year |
|---|---|
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Topics: Acrylamides; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Microvessels; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
Topics: Acetamides; Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidinones; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Tankyrases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Humans; MAP Kinase Kinase Kinases; Mice, Transgenic; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines | 2015 |
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cytoprotection; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Morpholines; Proto-Oncogene Proteins c-akt; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
Topics: Acrylamides; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Feeder Cells; Fluorescent Antibody Technique; Gene Expression; High-Throughput Screening Assays; Humans; Keratin-18; Keratin-8; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neoplasms; Piperazines; Precision Medicine; Primary Cell Culture; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2017 |
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lactams; Lactams, Macrocyclic; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Middle Aged; Mutation; Piperidines; Pyrazoles; Xenograft Model Antitumor Assays | 2019 |